NEAUTUS TCM (02206.HK): Offer Price Set at HKD 40.20, Hong Kong Tranche Oversubscribed 2,190.99 Times

NewTimeSpace News: On 10 November 2026, Sichuan Neautus Traditional Chinese Medicine Co., Ltd. (stock code: 02206) announced the final offer price and allotment results of its global offering, with the offer price set at HKD 40.20 per H share, plus a 1.0% brokerage fee, a 0.0027% SFC transaction levy, a 0.00015% AFRC transaction levy and a 0.00565% Stock Exchange trading fee, at the bottom of the HKD 40.20 to HKD 50.55 range, with trading expected to begin on 11 November 2026.

The announcement disclosed that the global offering comprises 6,517,300 H shares, of which 651,750 are under the Hong Kong public offer and 5,865,550 under the international offering, representing 10% and 90% of the global offering respectively; total issued shares upon listing will be 65,172,741, with a nominal value of RMB 1.00 per share. Gross proceeds are HKD 262.00 million and, after estimated listing expenses of HKD 64.54 million at the offer price, net proceeds are HKD 197.46 million.

The Company stated that the Hong Kong public offer received 58,843 valid applications, of which 12,729 were successful, with a subscription level of 2,190.99 times; no clawback was triggered and the final number of offer shares under the Hong Kong public offer remained 651,750. The international offering had 117 placees and a subscription level of 1.25 times, with a final 5,865,550 offer shares. Within the international offering, Ms. Cai Ying was allotted 512,500 shares, or 7.86% of the offer shares and 0.79% each of the total H shares and total issued share capital after the global offering; she is a close associate of existing shareholder Chengdu Yiyi Technology Co., Ltd., and the allotment was consented to by the Stock Exchange under paragraph 1C(2) of the Placing Guidelines.

The Company stated that controlling shareholders Mr. Jiang Yun, holding 18,498,500 H shares, and Guojia Investment, holding 9,151,965 H shares, are subject to lock-ups over 28.4% and 14.0% of total issued shares after the global offering, or 42.4% combined, until 10 November 2027; other existing shareholders, including Mr. Jiang Ercheng (16.3%), Pengjin Taihe (6.9%), Zhongzhi Pharmaceutical (3.5%) and Chengdu Yiyi (3.3%), are locked up until the same date. The announcement cautioned that, given the concentration of shareholding in a small number of shareholders, H-share prices may be volatile even on small trading volumes.